Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
The use of benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor, allowed patients with asthma who were dependent on oral glucocorticoids to reduce the glucocorticoid dose to a greater extent than those who received placebo. Asthma is a common chronic i...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2017-06, Vol.376 (25), p.2448-2458 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2458 |
|---|---|
| container_issue | 25 |
| container_start_page | 2448 |
| container_title | The New England journal of medicine |
| container_volume | 376 |
| creator | Nair, Parameswaran Wenzel, Sally Rabe, Klaus F Bourdin, Arnaud Lugogo, Njira L Kuna, Piotr Barker, Peter Sproule, Stephanie Ponnarambil, Sandhia Goldman, Mitchell |
| description | The use of benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor, allowed patients with asthma who were dependent on oral glucocorticoids to reduce the glucocorticoid dose to a greater extent than those who received placebo.
Asthma is a common chronic inflammatory disease of the airways that affects an estimated 315 million persons worldwide.
1
Approximately 5 to 10% of persons with asthma have a severe form of disease that is usually managed with high-dose inhaled glucocorticoids and bronchodilators.
2
,
3
Within this group, 32 to 45% of persons rely on frequent or maintenance use of oral glucocorticoid therapy.
4
,
5
Oral glucocorticoid therapy adversely affects health-related quality of life,
6
and effective alternative therapies without severe adverse effects are needed.
Eosinophilic inflammation is a key part of asthma, and increased numbers of circulating and airway eosinophils are accompanied by . . . |
| doi_str_mv | 10.1056/NEJMoa1703501 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01761510v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1912254125</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-77fa7115591e8ad9afbcfbeecd817a1c3556618b0181a2c48f6baa862d7006183</originalsourceid><addsrcrecordid>eNp10cFO3DAQBmALFcFCe-RaRaqQ4BCYSeLEOS5oy4IWONCerYljl6ySeLETpPbEO_CGfRKMdkEqUn0ZyfPp19jD2AHCCQLPT29mV9eWsICUA26xCfI0jbMM8k9sApCIOCvKdJfteb-EcDArd9huIngKIoMJm906aqOLdlRWWTc0yjb136fnuxW5pv8VzYzRaoisic50H2TzZ-yoipo-utOP2ulo6of7jj6zbUOt1182dZ_9_D77cT6PF7cXl-fTRayyEoa4KAwViJyXqAXVJZlKmUprVQssCFXKeZ6jqAAFUqIyYfKKSORJXQCERrrPjte599TKlWs6cr-lpUbOpwv5egdY5MgRHjHYo7VdOfswaj_IrvFKty312o5eYhkwD7MkgX77QJd2dH14SVCYJDzDhAcVr5Vy1nunzfsECPJ1F_KfXQT_dZM6Vp2u3_Xb5wdwuAZd52Wvl91_gl4AEPiN-g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1912254125</pqid></control><display><type>article</type><title>Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Nair, Parameswaran ; Wenzel, Sally ; Rabe, Klaus F ; Bourdin, Arnaud ; Lugogo, Njira L ; Kuna, Piotr ; Barker, Peter ; Sproule, Stephanie ; Ponnarambil, Sandhia ; Goldman, Mitchell</creator><creatorcontrib>Nair, Parameswaran ; Wenzel, Sally ; Rabe, Klaus F ; Bourdin, Arnaud ; Lugogo, Njira L ; Kuna, Piotr ; Barker, Peter ; Sproule, Stephanie ; Ponnarambil, Sandhia ; Goldman, Mitchell ; ZONDA Trial Investigators</creatorcontrib><description>The use of benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor, allowed patients with asthma who were dependent on oral glucocorticoids to reduce the glucocorticoid dose to a greater extent than those who received placebo.
Asthma is a common chronic inflammatory disease of the airways that affects an estimated 315 million persons worldwide.
1
Approximately 5 to 10% of persons with asthma have a severe form of disease that is usually managed with high-dose inhaled glucocorticoids and bronchodilators.
2
,
3
Within this group, 32 to 45% of persons rely on frequent or maintenance use of oral glucocorticoid therapy.
4
,
5
Oral glucocorticoid therapy adversely affects health-related quality of life,
6
and effective alternative therapies without severe adverse effects are needed.
Eosinophilic inflammation is a key part of asthma, and increased numbers of circulating and airway eosinophils are accompanied by . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa1703501</identifier><identifier>PMID: 28530840</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Administration, Oral ; Adult ; Anti-Asthmatic Agents - administration & dosage ; Anti-Asthmatic Agents - adverse effects ; Anti-Asthmatic Agents - therapeutic use ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - therapeutic use ; Asthma ; Asthma - drug therapy ; Clinical trials ; Cytokines ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug therapy ; Eosinophilia ; Female ; Glucocorticoids ; Glucocorticoids - administration & dosage ; Humans ; Immunosuppressive agents ; Injections, Subcutaneous ; Interleukin 5 ; Interleukin-5 Receptor alpha Subunit - antagonists & inhibitors ; Life Sciences ; Lungs ; Male ; Middle Aged ; Monoclonal antibodies ; Oral cavity ; Respiratory function</subject><ispartof>The New England journal of medicine, 2017-06, Vol.376 (25), p.2448-2458</ispartof><rights>Copyright © 2017 Massachusetts Medical Society. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c490t-77fa7115591e8ad9afbcfbeecd817a1c3556618b0181a2c48f6baa862d7006183</citedby><cites>FETCH-LOGICAL-c490t-77fa7115591e8ad9afbcfbeecd817a1c3556618b0181a2c48f6baa862d7006183</cites><orcidid>0000-0003-2401-0070 ; 0000-0002-4645-5209</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1703501$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa1703501$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>230,314,776,780,881,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28530840$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-01761510$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Nair, Parameswaran</creatorcontrib><creatorcontrib>Wenzel, Sally</creatorcontrib><creatorcontrib>Rabe, Klaus F</creatorcontrib><creatorcontrib>Bourdin, Arnaud</creatorcontrib><creatorcontrib>Lugogo, Njira L</creatorcontrib><creatorcontrib>Kuna, Piotr</creatorcontrib><creatorcontrib>Barker, Peter</creatorcontrib><creatorcontrib>Sproule, Stephanie</creatorcontrib><creatorcontrib>Ponnarambil, Sandhia</creatorcontrib><creatorcontrib>Goldman, Mitchell</creatorcontrib><creatorcontrib>ZONDA Trial Investigators</creatorcontrib><title>Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>The use of benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor, allowed patients with asthma who were dependent on oral glucocorticoids to reduce the glucocorticoid dose to a greater extent than those who received placebo.
Asthma is a common chronic inflammatory disease of the airways that affects an estimated 315 million persons worldwide.
1
Approximately 5 to 10% of persons with asthma have a severe form of disease that is usually managed with high-dose inhaled glucocorticoids and bronchodilators.
2
,
3
Within this group, 32 to 45% of persons rely on frequent or maintenance use of oral glucocorticoid therapy.
4
,
5
Oral glucocorticoid therapy adversely affects health-related quality of life,
6
and effective alternative therapies without severe adverse effects are needed.
Eosinophilic inflammation is a key part of asthma, and increased numbers of circulating and airway eosinophils are accompanied by . . .</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Anti-Asthmatic Agents - administration & dosage</subject><subject>Anti-Asthmatic Agents - adverse effects</subject><subject>Anti-Asthmatic Agents - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Asthma</subject><subject>Asthma - drug therapy</subject><subject>Clinical trials</subject><subject>Cytokines</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Drug therapy</subject><subject>Eosinophilia</subject><subject>Female</subject><subject>Glucocorticoids</subject><subject>Glucocorticoids - administration & dosage</subject><subject>Humans</subject><subject>Immunosuppressive agents</subject><subject>Injections, Subcutaneous</subject><subject>Interleukin 5</subject><subject>Interleukin-5 Receptor alpha Subunit - antagonists & inhibitors</subject><subject>Life Sciences</subject><subject>Lungs</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Oral cavity</subject><subject>Respiratory function</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp10cFO3DAQBmALFcFCe-RaRaqQ4BCYSeLEOS5oy4IWONCerYljl6ySeLETpPbEO_CGfRKMdkEqUn0ZyfPp19jD2AHCCQLPT29mV9eWsICUA26xCfI0jbMM8k9sApCIOCvKdJfteb-EcDArd9huIngKIoMJm906aqOLdlRWWTc0yjb136fnuxW5pv8VzYzRaoisic50H2TzZ-yoipo-utOP2ulo6of7jj6zbUOt1182dZ_9_D77cT6PF7cXl-fTRayyEoa4KAwViJyXqAXVJZlKmUprVQssCFXKeZ6jqAAFUqIyYfKKSORJXQCERrrPjte599TKlWs6cr-lpUbOpwv5egdY5MgRHjHYo7VdOfswaj_IrvFKty312o5eYhkwD7MkgX77QJd2dH14SVCYJDzDhAcVr5Vy1nunzfsECPJ1F_KfXQT_dZM6Vp2u3_Xb5wdwuAZd52Wvl91_gl4AEPiN-g</recordid><startdate>20170622</startdate><enddate>20170622</enddate><creator>Nair, Parameswaran</creator><creator>Wenzel, Sally</creator><creator>Rabe, Klaus F</creator><creator>Bourdin, Arnaud</creator><creator>Lugogo, Njira L</creator><creator>Kuna, Piotr</creator><creator>Barker, Peter</creator><creator>Sproule, Stephanie</creator><creator>Ponnarambil, Sandhia</creator><creator>Goldman, Mitchell</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0003-2401-0070</orcidid><orcidid>https://orcid.org/0000-0002-4645-5209</orcidid></search><sort><creationdate>20170622</creationdate><title>Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma</title><author>Nair, Parameswaran ; Wenzel, Sally ; Rabe, Klaus F ; Bourdin, Arnaud ; Lugogo, Njira L ; Kuna, Piotr ; Barker, Peter ; Sproule, Stephanie ; Ponnarambil, Sandhia ; Goldman, Mitchell</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-77fa7115591e8ad9afbcfbeecd817a1c3556618b0181a2c48f6baa862d7006183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Anti-Asthmatic Agents - administration & dosage</topic><topic>Anti-Asthmatic Agents - adverse effects</topic><topic>Anti-Asthmatic Agents - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Asthma</topic><topic>Asthma - drug therapy</topic><topic>Clinical trials</topic><topic>Cytokines</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Drug therapy</topic><topic>Eosinophilia</topic><topic>Female</topic><topic>Glucocorticoids</topic><topic>Glucocorticoids - administration & dosage</topic><topic>Humans</topic><topic>Immunosuppressive agents</topic><topic>Injections, Subcutaneous</topic><topic>Interleukin 5</topic><topic>Interleukin-5 Receptor alpha Subunit - antagonists & inhibitors</topic><topic>Life Sciences</topic><topic>Lungs</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Oral cavity</topic><topic>Respiratory function</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nair, Parameswaran</creatorcontrib><creatorcontrib>Wenzel, Sally</creatorcontrib><creatorcontrib>Rabe, Klaus F</creatorcontrib><creatorcontrib>Bourdin, Arnaud</creatorcontrib><creatorcontrib>Lugogo, Njira L</creatorcontrib><creatorcontrib>Kuna, Piotr</creatorcontrib><creatorcontrib>Barker, Peter</creatorcontrib><creatorcontrib>Sproule, Stephanie</creatorcontrib><creatorcontrib>Ponnarambil, Sandhia</creatorcontrib><creatorcontrib>Goldman, Mitchell</creatorcontrib><creatorcontrib>ZONDA Trial Investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nair, Parameswaran</au><au>Wenzel, Sally</au><au>Rabe, Klaus F</au><au>Bourdin, Arnaud</au><au>Lugogo, Njira L</au><au>Kuna, Piotr</au><au>Barker, Peter</au><au>Sproule, Stephanie</au><au>Ponnarambil, Sandhia</au><au>Goldman, Mitchell</au><aucorp>ZONDA Trial Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2017-06-22</date><risdate>2017</risdate><volume>376</volume><issue>25</issue><spage>2448</spage><epage>2458</epage><pages>2448-2458</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>The use of benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor, allowed patients with asthma who were dependent on oral glucocorticoids to reduce the glucocorticoid dose to a greater extent than those who received placebo.
Asthma is a common chronic inflammatory disease of the airways that affects an estimated 315 million persons worldwide.
1
Approximately 5 to 10% of persons with asthma have a severe form of disease that is usually managed with high-dose inhaled glucocorticoids and bronchodilators.
2
,
3
Within this group, 32 to 45% of persons rely on frequent or maintenance use of oral glucocorticoid therapy.
4
,
5
Oral glucocorticoid therapy adversely affects health-related quality of life,
6
and effective alternative therapies without severe adverse effects are needed.
Eosinophilic inflammation is a key part of asthma, and increased numbers of circulating and airway eosinophils are accompanied by . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>28530840</pmid><doi>10.1056/NEJMoa1703501</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-2401-0070</orcidid><orcidid>https://orcid.org/0000-0002-4645-5209</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2017-06, Vol.376 (25), p.2448-2458 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_01761510v1 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Administration, Oral Adult Anti-Asthmatic Agents - administration & dosage Anti-Asthmatic Agents - adverse effects Anti-Asthmatic Agents - therapeutic use Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Asthma Asthma - drug therapy Clinical trials Cytokines Dose-Response Relationship, Drug Double-Blind Method Drug therapy Eosinophilia Female Glucocorticoids Glucocorticoids - administration & dosage Humans Immunosuppressive agents Injections, Subcutaneous Interleukin 5 Interleukin-5 Receptor alpha Subunit - antagonists & inhibitors Life Sciences Lungs Male Middle Aged Monoclonal antibodies Oral cavity Respiratory function |
| title | Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T03%3A50%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20Glucocorticoid%E2%80%93Sparing%20Effect%20of%20Benralizumab%20in%20Severe%20Asthma&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Nair,%20Parameswaran&rft.aucorp=ZONDA%20Trial%20Investigators&rft.date=2017-06-22&rft.volume=376&rft.issue=25&rft.spage=2448&rft.epage=2458&rft.pages=2448-2458&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa1703501&rft_dat=%3Cproquest_hal_p%3E1912254125%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1912254125&rft_id=info:pmid/28530840&rfr_iscdi=true |